NCT07457918Phase 3Recruiting

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

Study sponsor: Verrica Pharmaceuticals Inc. · VRCA

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2028-04-30Estimated

Enrollment · participants600Estimated

Source updated2026-05-05Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-05-05 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Common Warts (Verruca Vulgaris); Common Warts; Human Papilloma Virus (HPV); Warts

Treatments or interventions studied

Not recorded

Primary outcomes · main study measures

Read the study measures

measure: Incidence and severity of AEs including LSRs.; description: To assess the safety of YCANTH (VP-102/TO-208) by assessing adverse events (AEs), including expected local skin reactions (LSRs).; timeFrame: Day of transition to this LTFU study to End of Study Visit Day 378.; measure: Change from baseline in vital signs (body temperature); description: To assess the safety of YCANTH (VP-102/TO-208) by assessing the change from baseline body temperature.; timeFrame: Day of transition to this LTFU study to End of Study Visit Day 378.; measure: Change from baseline in vital signs (pulse); description: To assess the safety of YCANTH (VP-102/TO-208) by assessing the change in baseline in vital signs (pulse).; timeFrame: Day of transition to this LTFU study to End of Study Visit Day 378.; measure: Concomitant medication use; description: To assess the safety of YCANTH (VP-102/TO-208) by assessing concomitant medication use.; timeFrame: Day of transition to this LTFU study to End of Study Visit Day 378.; measure: Proportion of subjects achieving clearance (reduction to zero) at the Day 378 EOS Visit of all treatable warts present at Baseline*; description: To evaluate the efficacy of continued dermal application of YCANTH (VP-102/TO-208) when applied to each common wart once every 21 days for a maximum of 4 additional treatments. \*Baseline in the study will be either 1) Treatment Visit 1 (Day 1) of the parent study for subjects who received YCANTH (VP-102/TO-208) during the parent study; 2) the first Treatment Visit of this study for subjects who received Vehicle in the parent study; or 3) Treatment Visit 1 of the parent study for subjects who received Vehicle in the parent study and did not receive YCANTH (VP-102/TO-208) during this study.; timeFrame: Baseline* to End of Study Visit Day 378.

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history